Jean-paul P. Fermand

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

Journal: Blood cancer journal

Published: July 07, 2025

Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma.

Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma.

Journal: Cancer immunology research

Published: October 10, 2023

CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment.

CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment.

Journal: EJHaem

Published: April 28, 2022

Randall-Type Monoclonal Immunoglobulin Deposition Disease: New Insights into the Pathogenesis, Diagnosis and Management.

Randall-Type Monoclonal Immunoglobulin Deposition Disease: New Insights into the Pathogenesis, Diagnosis and Management.

Journal: Diagnostics (Basel, Switzerland)

Published: February 04, 2021

Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.

Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 31, 2020

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma.

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma.

Journal: Haematologica

Published: July 18, 2020

Results of a nation-wide cohort study suggest favorable long-term outcomes of clone-targeted chemotherapy in immunotactoid glomerulopathy.

Results of a nation-wide cohort study suggest favorable long-term outcomes of clone-targeted chemotherapy in immunotactoid glomerulopathy.

Journal: Kidney international

Published: February 29, 2020

High cutoff haemodialysis in myeloma cast nephropathy: further investigation is needed.

High cutoff haemodialysis in myeloma cast nephropathy: further investigation is needed.

Journal: The Lancet. Haematology

Published: April 16, 2019

Monoclonal gammopathy related disorders

Monoclonal gammopathy related disorders

Journal: La Revue du praticien

Published: March 15, 2019

Myeloma and other monoclonal gammopathies: a lot of progress and a lot of hopes

Myeloma and other monoclonal gammopathies: a lot of progress and a lot of hopes

Journal: La Revue du praticien

Published: March 15, 2019

The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Journal: Nature reviews. Nephrology

Published: December 05, 2018

Coexisting cutaneous macroglobulinosis and scleredema of Buschke in a patient with a Waldenström Macroglobulinemia.

Coexisting cutaneous macroglobulinosis and scleredema of Buschke in a patient with a Waldenström Macroglobulinemia.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: September 30, 2018

Showing 1-12 of 50

Last Updated: 09/26/2026